{"schema_version":"1.0","type":"article","title":"Novo Nordisk’s 6,300-Patient ZEUS Failure: A Textbook Lesson in Translational Risk","url":"https://drugnews.com.tw/articles/2026-08-13-ziltivekimab-zeus-mace-phase3-failure-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-08-13-ziltivekimab-zeus-mace-phase3-failure-en.md","lang":"en","date":"2026-08-13","publish_at":"2026-08-13T08:00:00+08:00","updated_at":"2026-08-13","category":"商業分析系列","topic":"商業分析系列","tags":["Novo Nordisk","ziltivekimab","ZEUS","MACE","IL-6","hsCRP","cardiovascular outcomes","Phase 3","biomarker risk"],"summary":"ZEUS showed the central translational risk in cardiovascular drug development: ziltivekimab suppressed the IL-6 pathway, but the 6,300-patient outcomes trial did not reduce three-point MACE.","key_points":[],"facts":[],"sections":["01 | A Phase 2 star, a Phase 3 miss","02 | RESCUE really was strong, but it answered a different question","03 | Three layers investors must not confuse","04 | Two hypotheses, neither proven yet","05 | Cardiovascular history is full of beautiful markers that failed","06 | Three questions before trusting a beautiful Phase 2 curve","Conclusion | Every beautiful early chart is only a premise","References","Disclaimer"],"references":[{"title":"[Novo Nordisk ZEUS headline results]","source":"","date":"","url":"https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916587"},{"title":"[ZEUS study registration]","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT05021835"},{"title":"[RESCUE phase 2 trial]","source":"","date":"","url":"https://pubmed.ncbi.nlm.nih.gov/34015342/"},{"title":"[ILLUMINATE]","source":"","date":"","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa0706628"},{"title":"[PROMINENT]","source":"","date":"","url":"https://pubmed.ncbi.nlm.nih.gov/36342113/"},{"title":"[STABILITY]","source":"","date":"","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1315878"},{"title":"[VISTA-16]","source":"","date":"","url":"https://pubmed.ncbi.nlm.nih.gov/24247616/"},{"title":"[NORVIT]","source":"","date":"","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa055227"},{"title":"[CANTOS]","source":"","date":"","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1707914"},{"title":"[LoDoCo2]","source":"","date":"","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2021372"}],"images":[{"alt":"Figure 1 | ZEUS enrolled more than 6,300 patients; inflammation markers fell, but three-point MACE did not improve.","url":"https://drugnews.com.tw/assets/articles/ziltivekimab-zeus-mace-phase3-failure-en/figure-01.png"},{"alt":"Figure 2 | RESCUE and ZEUS answered different questions: biomarker response is not outcome proof.","url":"https://drugnews.com.tw/assets/articles/ziltivekimab-zeus-mace-phase3-failure-en/figure-02.png"},{"alt":"Figure 3 | Risk markers, pharmacodynamic markers, and surrogate endpoints sit on different evidence layers.","url":"https://drugnews.com.tw/assets/articles/ziltivekimab-zeus-mace-phase3-failure-en/figure-03.png"},{"alt":"Figure 4 | What ZEUS tells us, what remains unknown, and what investors should not extrapolate.","url":"https://drugnews.com.tw/assets/articles/ziltivekimab-zeus-mace-phase3-failure-en/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/ziltivekimab-zeus-mace-phase3-failure-en/cover-1400.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-08-13）。Novo Nordisk’s 6,300-Patient ZEUS Failure: A Textbook Lesson in Translational Risk。https://drugnews.com.tw/articles/2026-08-13-ziltivekimab-zeus-mace-phase3-failure-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-08-13-ziltivekimab-zeus-mace-phase3-failure.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}